FREMONT, Calif., Nov. 07, 2017 -- ACM Research, Inc. (NASDAQ:ACMR) announced today the closing of its initial public offering of 2,000,000 shares of its Class A common stock at a price to the public of $5.60 per share, before underwriting discounts and commissions. The shares began trading on The Nasdaq Global Market Stock Exchange on November 3, 2017 under the symbol “ACMR.” In addition, ACM Research has granted the underwriters a 30-day option to purchase up to 300,000 additional shares of Class A common stock at the initial public offering price, less underwriting discounts and commissions.
ACM Research also announced the closing of a concurrent private placement of 833,334 shares of Class A common stock to Xinxin (Hongkong) Capital Co., Limited, a subsidiary of Sino IC Capital Co., Ltd., and 500,000 shares of Class A common stock to Victorious Way Limited at a price per share equal to $5.60 per share.
The gross proceeds to ACM Research from the initial public offering and the concurrent private placement totaled approximately $18.7 million, before deducting underwriting discounts and commissions, placement fees and offering expenses.
Roth Capital Partners acted as sole book-running manager for the initial public offering. Craig-Hallum Capital Group and The Benchmark Company acted as co-managers for the initial public offering.
A registration statement relating to and describing the terms of the initial public offering was declared effective by the U.S. Securities and Exchange Commission on November 2, 2017. The initial public offering was made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained from Roth Capital Partners, Attn: Prospectus Department, 888 San Clemente Drive, Suite 400, Newport Beach, California 92660, telephone: 1-800-678-9147 or by accessing the SEC’s website, www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ACM Research, Inc.
ACM Research Inc. develops, manufactures and sells single-wafer wet cleaning equipment, which semiconductor manufacturers can use in numerous manufacturing steps to remove particles, contaminants and other random defects, and thereby improve product yield, in fabricating advanced integrated circuits.
For investor and media inquiries, please contact:
In the United States:
The Blueshirt Group
Mr. Ralph Fong
+1 (415) 489-2195
[email protected]
In China:
The Blueshirt Group Asia
Mr. Gary Dvorchak, CFA
+86 (138) 1079-1480
[email protected]


Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings
How Marco Pharma International Preserves German Homeopathic Traditions in America 



